









Markets
/
Stocks
/
nasdaq-tbph
/

Theravance Biopharma Inc

TBPH

14.470USD

+0.420+2.99%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

728.72MMarket Cap

55.92P/E TTM



Theravance Biopharma Inc

14.470

+0.420+2.99%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

8 / 175

Overall Ranking

60 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

20.000

Target Price

+42.35%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.39% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.38M.

Overvalued

The company’s latest PE is 57.38, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.49M shares, decreasing 16.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.16M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.59.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 9.55, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 26.20M, representing a year-over-year increase of 83.75%, while its net profit experienced a year-over-year increase of 431.75%.

Score

Industry at a Glance

Previous score

9.55

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.73

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.02, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 55.71, which is -98.44% below the recent high of 0.87 and 116.15% above the recent low of -9.00.

Score

Industry at a Glance

Previous score

2.02

Change

-0.08

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 8/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 7.60, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Theravance Biopharma Inc is 20.00, with a high of 28.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

20.000

Target Price

+42.35%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Theravance Biopharma Inc

TBPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 7.24, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 14.65 and the support level at 13.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

1.74

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.094

Neutral

RSI(14)

67.073

Neutral

STOCH(KDJ)(9,3,3)

78.218

Buy

ATR(14)

0.460

High Vlolatility

CCI(14)

145.510

Buy

Williams %R

7.407

Overbought

TRIX(12,20)

0.508

Sell

StochRSI(14)

58.110

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

14.218

Buy

MA10

14.006

Buy

MA20

13.925

Buy

MA50

12.571

Buy

MA100

11.395

Buy

MA200

10.357

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 96.98%, representing a quarter-over-quarter decrease of 0.96%. The largest institutional shareholder is The Vanguard, holding a total of 2.16M shares, representing 4.28% of shares outstanding, with 5.17% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Madison Avenue Partners LP

9.51M

Weiss Asset Management

7.46M

Newtyn Management, LLC

4.76M

BlackRock Institutional Trust Company, N.A.

3.04M

-4.04%

Irenic Capital Management LP

2.76M

The Vanguard Group, Inc.

Star Investors

2.08M

+3.87%

Park West Asset Management LLC

1.80M

+0.63%

Winningham (Rick E)

1.31M

-2.21%

Oasis Management Company Ltd.

1.12M

+0.28%

State Street Global Advisors (US)

1.07M

-12.74%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 6.01, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is -0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.